Trial of Rapid-acting Intranasal Esketamine for Treatment-resistant Major Depressive Disorder (TRANSFORM-2)

Brief Description Of Study

We are currently enrolling participants for a clinical research study to look at the effectiveness and safety of an investigational medication (given as a nasal spray) in patients with depression who have not responded to prior treatment with at least two antidepressants. If you are eligible for this study and choose to participate, you will receive all study visits and study-related medical care at no cost to you. Compensation for your time and travel may also be provided.

Clinical Study Identifier: TX1047

Detailed Study Description

There are three phases in the study: • A screening phase of up to 7 weeks • A 4-week treatment phase • A 24-week follow-up phase o Some patients will be given the option to continue treatment in another study and will not have a follow-up phase. Patients who do not have a follow-up phase will be in the study for 11 weeks; all other patients will be in the study for 35 weeks

Additional Information About The Study

To be considered for this study, you must be: • 18 to 64 years old • Diagnosed with depression • Experiencing depression symptoms despite having taken two antidepressant medications in the past • Comfortable with using a nasal spray • Able to provide written consent to participate in the study The study doctor will discuss additional requirements for being in the study with you.

Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: Trial of Rapid-acting Intranasal Esketamine for Treatment-resistant Major Depressive Disorder (TRANSFORM-2)
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.